-
2024-510805-27-00
5
2025-01-09
Sickle Cell Disease and Thalassaemia
-
2024-513420-41-00
10
2025-01-09
prematurity in neonates
-
2024-519969-21-00
6
2025-01-01
Infective endocarditis
-
2024-511497-79-00
4
2024-12-30
Hormone receptor positive (HR+), human epidermal growth factor recepto
-
2022-500455-23-00
5
2024-12-11
Candidemia
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-511465-11-00
5
2024-11-20
Spontaneous lobar ICH
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-511719-40-00
6
2024-10-09
Enterococcus faecalis infectious endocarditis
-
2023-508258-24-00
4
2024-09-12
Ovarian cancer (OC) with oligometastatic progression (OMP).
-
2023-510536-37-00
4
2024-07-05
Prostate Cancer
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-505024-62-01
4
2024-05-16
Oligometastatic patients with castration-resistant
prostate cancer
-
2023-508442-18-00
5
2024-04-14
Patients with an infection of the osteosynthesis material implanted af
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2022-502282-24-00
5
2024-02-14
Primary generalized tonic-clonic seizures
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2023-505426-34-01
6
2023-12-18
chronic rhinosinusitis (CRS)